Negative HBcAg in immunohistochemistry assay of liver biopsy is a predictive factor for the treatment of patients with nucleos(t)ide analogue therapy
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cellular and Molecular Medicine"
DOI: 10.1111/jcmm.13444
Abstract: The hepatitis B core antigen (HBcAg) is an important target for antiviral response in chronic hepatitis B (CHB) patients. However, the correlation between HBcAg in the hepatocyte nucleus and nucleos(t)ide analogue (NA) therapeutic response is… read more here.
Keywords: week; nucleos ide; ide analogue; hbcag group ... See more keywords
TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China
Sign Up to like & getrecommendations! Published in 2017 at "BioMed Research International"
DOI: 10.1155/2017/2463197
Abstract: Background/Aims Many patients had to transfer to tenofovir disoproxil fumarate (TDF) if there is other nucleos(t)ide analogue (NA) resistance. We aimed to investigate antiviral effects of TDF monotherapy between NA-naive and NA-experienced chronic hepatitis B… read more here.
Keywords: nucleos ide; tdf monotherapy; ide analogue; dna ... See more keywords
Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
Sign Up to like & getrecommendations! Published in 2018 at "World Journal of Gastroenterology"
DOI: 10.3748/wjg.v24.i17.1825
Abstract: Chronic hepatitis B (CHB) remains a challenging global health problem, with nearly one million related deaths per year. Nucleos(t)ide analogue (NA) treatment suppresses viral replication but does not provide complete cure of the hepatitis B… read more here.
Keywords: nucleos ide; ide analogue; hepatitis; treatment ... See more keywords